Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Sees Large Decrease in Short Interest

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 398,700 shares, a drop of 17.2% from the January 31st total of 481,400 shares. Based on an average trading volume of 669,500 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Friday, February 28th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently made changes to their positions in MIST. BML Capital Management LLC boosted its stake in Milestone Pharmaceuticals by 3.0% in the 3rd quarter. BML Capital Management LLC now owns 1,136,091 shares of the company’s stock worth $1,727,000 after purchasing an additional 33,196 shares during the period. Toronto Dominion Bank bought a new stake in shares of Milestone Pharmaceuticals in the fourth quarter valued at about $1,770,000. Boxer Capital Management LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth about $729,000. Virtu Financial LLC acquired a new position in shares of Milestone Pharmaceuticals during the fourth quarter worth about $170,000. Finally, Northern Trust Corp grew its holdings in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock worth $137,000 after buying an additional 30,772 shares in the last quarter. Institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Trading Down 4.5 %

Shares of Milestone Pharmaceuticals stock traded down $0.09 during trading hours on Friday, hitting $1.82. The company’s stock had a trading volume of 698,668 shares, compared to its average volume of 352,919. Milestone Pharmaceuticals has a 12 month low of $1.12 and a 12 month high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The company has a market capitalization of $96.79 million, a PE ratio of -2.24 and a beta of 1.83. The stock has a 50 day moving average of $2.05 and a 200 day moving average of $1.77.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.